Hypoglycemia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hypoglycemia – Pipeline Review, H1 2017’, provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypoglycemia

The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects

The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypoglycemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypoglycemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Eiger BioPharmaceuticals Inc

Eli Lilly and Company

Heptares Therapeutics Ltd

Novartis AG

Therakind Ltd

USV Pvt Ltd

Vectura Group Plc

XERIS Pharmaceuticals Inc

XOMA Corp

Zealand Pharma AS

Zucara Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoglycemia - Overview

Hypoglycemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia - Companies Involved in Therapeutics Development

Eiger BioPharmaceuticals Inc

Eli Lilly and Company

Heptares Therapeutics Ltd

Novartis AG

Therakind Ltd

USV Pvt Ltd

Vectura Group Plc

XERIS Pharmaceuticals Inc

XOMA Corp

Zealand Pharma AS

Zucara Therapeutics Inc

Hypoglycemia - Drug Profiles

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143753 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3185643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-900018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRL-2903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbutaline sulphate MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoglycemia - Dormant Projects

Hypoglycemia - Discontinued Products

Hypoglycemia - Product Development Milestones

Featured News & Press Releases

Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery

Dec 13, 2016: Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics

Dec 12, 2016: Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia

Nov 29, 2016: Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia

Oct 17, 2016: Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency

Sep 15, 2016: XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies

Sep 06, 2016: XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016

Aug 11, 2016: Phase II results with dasiglucagon (ZP4207) support its potential for use in a ready-to-use rescue pen to treat severe hypoglycemia in diabetes

Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia

May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery

Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery

Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting

Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes

Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism

Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand’s stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypoglycemia, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hypoglycemia – Pipeline by Eiger BioPharmaceuticals Inc, H1 2017

Hypoglycemia – Pipeline by Eli Lilly and Company, H1 2017

Hypoglycemia – Pipeline by Heptares Therapeutics Ltd, H1 2017

Hypoglycemia – Pipeline by Novartis AG, H1 2017

Hypoglycemia – Pipeline by Therakind Ltd, H1 2017

Hypoglycemia – Pipeline by USV Pvt Ltd, H1 2017

Hypoglycemia – Pipeline by Vectura Group Plc, H1 2017

Hypoglycemia – Pipeline by XERIS Pharmaceuticals Inc, H1 2017

Hypoglycemia – Pipeline by XOMA Corp, H1 2017

Hypoglycemia – Pipeline by Zealand Pharma AS, H1 2017

Hypoglycemia – Pipeline by Zucara Therapeutics Inc, H1 2017

Hypoglycemia – Dormant Projects, H1 2017

Hypoglycemia – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Hypoglycemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports